Showing results (2151-2160 of 2,243) with videos related to

Sort By:
Pageof 225
BMC Cardiovascular Disorders|October 9, 2025
Blood pressure at age 40 and key features of cerebral small vessel disease at age 70: data from the ACE 1950 StudyMarte M Walle-Hansen, Guri Hagberg, Marius Myrstad, et al.
BMJ (Clinical Research Ed.)|November 22, 2019
Induction of labour at 41 weeks versus expectant management and induction of labour at 42 weeks (SWEdish Post-term Induction Study, SWEPIS): multicentre, open label, randomised, superiority trialUlla-Britt Wennerholm, Sissel Saltvedt, Anna Wessberg, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 28, 2005
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosisMattias Berglund, Ulf Thunberg, Rose-Marie Amini, et al.
Genes & Development|July 24, 2021
Single-cell atlas reveals meningeal leukocyte heterogeneity in the developing mouse brainAura Zelco, Vanja Börjesson, Jurrian K de Kanter, et al.
Circulation|August 13, 2016
Cardiovascular Health Promotion in Children: Challenges and Opportunities for 2020 and Beyond: A Scientific Statement From the American Heart AssociationJulia Steinberger, Stephen R Daniels, Nancy Hagberg, et al.
Plos One|May 13, 2021
Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppressionMagnus Gisslen, Sheila M Keating, Serena Spudich, et al.
The American Journal of Pathology|December 18, 2017
γδ T Cells Contribute to Injury in the Developing BrainAnna-Maj Albertsson, Xiaoli Zhang, Regina Vontell, et al.
Journal of the Neurological Sciences|July 2, 2026
Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot studyGisle Berg Helland, Brian Enriquez, Mona K Beyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Pageof 225